A Phase I Study of T900607 given once every three weeks in patients with advanced refractory cancer.
Phase of Trial: Phase I
Latest Information Update: 24 May 2014
At a glance
- Drugs T 900607 (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 10 Feb 2006 New trial record.